Drug Targets – Products

DNAnexus and Alida Biosciences collaborate to advance RNA epigenomics by hosting AlidaBio's EpiScout™ Analysis Suite on the DNAnexus cloud platform.

This article introduces the role of kinases in neurodegenerative diseases, the development of kinase inhibitors for the treatment of AD, PD, and ALS, as well as the challenges in developing kinase-targeted drugs

This article reviews pathological and physiological role of Tau proteins in neurodegeneration, Tau-targeted drug development strategies, and SignalChem’s contribution

SignalChem Biotech, part of Sino Biological, offers one of the largest active enzyme collections in the world and specializes in comprehensive in vitro compound screening services, from low to medium throughput

Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance.

Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces the signing of a new development contract with a rare disease biopharmaceutical company.

AMSBIO announce a new range of Synthetic Nanodiscs that enable preparation of multi-pass transmembrane proteins in their active form, revolutionizing the future of membrane protein research and drug development.

Sino Biological is at the forefront of accelerating Mpox research, offering a comprehensive portfolio of MPXV proteins and antibodies.

On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.